PNC Financial Services Group’s Radiopharm Theranostics RADX Stock Holding History

PNC Financial Services Group’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$81K	Buy	50,000 +30,000	+150%	+$83.9K	﹤0.01%	3091
2026 Q2	$83.8K	Buy	20,000 +4,000	+25%	+$17.8K	﹤0.01%	3044
2026 Q1	$68.8K	Hold	16,000	–	–	﹤0.01%	3029
2025 Q4	$83.5K	Hold	16,000	–	–	﹤0.01%	2915
2025 Q3	$88.3K	Buy	16,000 +8,000	+100%	+$41.9K	﹤0.01%	2893
2025 Q2	$37.1K	Buy	+8,000	New	+$35.9K	﹤0.01%	3279

Other funds holding RADX

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

PNC Financial Services Group's RADX Position: Q3 2026 in Review

PNC Financial Services Group increased its Radiopharm Theranostics (RADX) stake by 150% in Q3 2026, buying an estimated $83.9K and bringing the position to 50,000 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #3091.

PNC Financial Services Group first reported a position in RADX in Q2 2025 and has held it in 6 quarters since. The position peaked at $88.3K in Q3 2025. 3 funds tracked by Wall St. Rank hold RADX as of Q3 2026.

PNC Financial Services Group held 50,000 shares of Radiopharm Theranostics worth $81K as of Q3 2026.
PNC Financial Services Group bought 30,000 Radiopharm Theranostics shares in Q3 2026, an estimated $83.9K.
Radiopharm Theranostics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3091 holding.
PNC Financial Services Group first reported a position in Radiopharm Theranostics in Q2 2025 and has held it in 6 quarters since.
PNC Financial Services Group's Radiopharm Theranostics position peaked at $88.3K in Q3 2025.
3 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.